Drugs / Amantadin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00821691 | Mar 2009 → Apr 2013 | cerebral infarction | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amantadin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00821691 ↗ |
| Known as | amantadine | “The objective of the study is to test the action of the amantadine, as DOPA-agonist, in a double blind cross-over trial, amantadine / placebo, on the verbal fluency of chronic...” NCT00821691 ↗ |